Pandion, Astellas team up on immunomodulators for pancreatic diseases
Category: #health  By Mateen Dalal  Date: 2019-10-31
  • share
  • Twitter
  • Facebook
  • LinkedIn

Pandion, Astellas team up on immunomodulators for pancreatic diseases

Pandion Therapeutics, Inc. and Astellas Pharma Inc. have reportedly inked a license and collaboration deal for researching, developing and commercializing pancreas-targeting immunomodulators.

The companies will work on locally acting immunomodulators for pancreatic autoimmune diseases, by combining the advanced therapeutics development and commercialization expertise of Astellas with functional immunology and modular biologics capabilities of Pandion. Pandion is slated to receive around $45 million in upfront and further payments associated with research and preclinical work.

According to the terms of the deal, Pandion would be designing and discovering bispecific drug candidates, based on the company’s proprietary immune effector and tissue tether platform. On the other hand, Astellas will conduct preclinical activities, clinical studies and be responsible for commercialization activities for the specific candidates developed through the partnership.

In case Astellas is able to develop and commercialize several candidates for multiple autoimmune diseases of the pancreas, Pandion could be awarded over $750 million by Astellas as future development and commercial milestone achievements. For any product developed under the partnership, Pandion is eligible to earn royalties on global net sales as well.

Astellas’ CSO and CFO, Naoki Okamura said that antigen-specific immune modulation (ASIM) is among the strategic fields being focused on primarily, and the company is involved in developing innovative treatments for autoimmune diseases through new technologies.

The tissue-specific immune modulation technology of Pandion is expected to be a possible next-gen ASIM modality, that could help expand it application scope to other autoimmune diseases, Okamura added.

According to Rahul Kakkar, MD, Pandion CEO, Astellas is a partner having a strategic vision for the capabilities of local immunomodulation in Type 1 diabetes and significant commitment towards immunology. It will help boost Pandion’s R&D activities and build upon its existing partnership with the JDRF T1D Fund.

Kakkar mentioned that in Type 1 diabetes, patient’s pancreas undergo autoimmune destruction. Pandion’s tissue targeted immune effectors aim to address this immune response directly, modifying the diseases and the site of the immune attack.
 

Source Credits: https://www.astellas.com/en/news/15396

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More

More News By Mateen Dalal

FDA approves ‘Rukobia’ for HIV patients with limited treatment options
FDA approves ‘Rukobia’ for HIV patients with limited treatment options
By Mateen Dalal

The use of antiretroviral therapies (ART) to battle HIV (Human Immunodeficiency Virus) is one of the great achievements of modern medicine. The ART medications can transform HIV from a fatal infection into a more manageable, chronic disease. As per t...

UK market regulators inspect Apple’s search engine deal with Google
UK market regulators inspect Apple’s search engine deal with Google
By Mateen Dalal

The U.K. Competition and Markets Authority has recently revealed that payments by Google to Apple Inc. to become the default search engine on the tech firm’s Safari web browser creates a barrier to entry and expansion for the search engine gian...

Amazon Web Services forays into aerospace & satellite business
Amazon Web Services forays into aerospace & satellite business
By Mateen Dalal

Amazon Web Services (AWS), a cloud computing subsidiary of Amazon, has officially announced the launch of Aersopace and Satellite Solutions, its dedicated business unit for space projects which boasts of customers like NASA, the U.S. military, and pr...